Lipoprotein disorders prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m Bot: Removing from Primary care |
||
| (7 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}} | {{CMG}} | ||
{{Hyperlipidemia}} | {{Hyperlipidemia}} | ||
==Prevention== | ==Prevention== | ||
=== United States Preventive Services Task Force (USPSTF) Screening for Lipid Disorders in Adults <ref name="pmid12394084">{{cite journal| author=Berg AO, Atkins D, U.S. Preventive Services Task Force| title=U.S. Preventive Services Task Force: screening for lipid disorders in adults: recommendations and rationale. | journal=Am J Nurs | year= 2002 | volume= 102 | issue= 6 | pages= 91, 93, 95 | pmid=12394084 | doi= | pmc= | url= }} </ref> (DO NOT EDIT)=== | === United States Preventive Services Task Force (USPSTF) Screening for Lipid Disorders in Adults<ref name="pmid12394084">{{cite journal| author=Berg AO, Atkins D, U.S. Preventive Services Task Force| title=U.S. Preventive Services Task Force: screening for lipid disorders in adults: recommendations and rationale. | journal=Am J Nurs | year= 2002 | volume= 102 | issue= 6 | pages= 91, 93, 95 | pmid=12394084 | doi= | pmc= | url= }} </ref> (DO NOT EDIT)=== | ||
{{cquote| | {{cquote| | ||
===Screening Men=== | ====Screening Men==== | ||
'''1)''' The USPSTF strongly recommends screening men aged 35 and older for lipid disorders. (Grade A recommendation) | '''1)''' The USPSTF strongly recommends screening men aged 35 and older for lipid disorders. (Grade A recommendation) | ||
| Line 26: | Line 16: | ||
'''2)''' The USPSTF recommends screening men aged 20 to 35 for lipid disorders if they are at increased risk for CHD. (Grade B recommendation) | '''2)''' The USPSTF recommends screening men aged 20 to 35 for lipid disorders if they are at increased risk for CHD. (Grade B recommendation) | ||
===Screening Women at Increased Risk=== | ====Screening Women at Increased Risk==== | ||
'''1)''' The USPSTF strongly recommends screening women aged 45 and older for lipid disorders if they are at increased risk for [[coronary heart disease]]. (Grade A recommendation) | '''1)''' The USPSTF strongly recommends screening women aged 45 and older for lipid disorders if they are at increased risk for [[coronary heart disease]]. (Grade A recommendation) | ||
| Line 32: | Line 22: | ||
'''2)''' The USPSTF recommends screening women aged 20 to 45 for lipid disorders if they are at increased risk for CHD. (Grade B recommendation) | '''2)''' The USPSTF recommends screening women aged 20 to 45 for lipid disorders if they are at increased risk for CHD. (Grade B recommendation) | ||
===Screening of Young Men and All Women Not at Increased Risk=== | ====Screening of Young Men and All Women Not at Increased Risk==== | ||
'''1)''' The USPSTF makes no recommendation for or against routine screening for lipid disorders in men aged 20 to 35, or in women aged 20 and older who are not at increased risk for CHD. (Grade C recommendation) | '''1)''' The USPSTF makes no recommendation for or against routine screening for lipid disorders in men aged 20 to 35, or in women aged 20 and older who are not at increased risk for CHD. (Grade C recommendation) | ||
===Clinical Considerations=== | ====Clinical Considerations==== | ||
'''1)''' An age to stop screening has not been established. Screening may be appropriate in older people who have never been screened; repeated screening is less important in older people because lipid levels are less likely to increase after age 65. However, because older adults have an increased baseline risk for coronary heart disease, they stand to gain greater absolute benefit from the treatment of dyslipidemia, compared with younger adults. | '''1)''' An age to stop screening has not been established. Screening may be appropriate in older people who have never been screened; repeated screening is less important in older people because lipid levels are less likely to increase after age 65. However, because older adults have an increased baseline risk for coronary heart disease, they stand to gain greater absolute benefit from the treatment of dyslipidemia, compared with younger adults. | ||
| Line 47: | Line 37: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Lipid disorders]] | [[Category:Lipid disorders]] | ||
| Line 52: | Line 43: | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
[[Category:Metabolic disorders]] | [[Category:Metabolic disorders]] | ||
[[Category:Needs overview]] | |||
Latest revision as of 22:31, 29 July 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
|
Lipoprotein Disorders Microchapters |
Prevention
United States Preventive Services Task Force (USPSTF) Screening for Lipid Disorders in Adults[1] (DO NOT EDIT)
| “ |
Screening Men1) The USPSTF strongly recommends screening men aged 35 and older for lipid disorders. (Grade A recommendation) 2) The USPSTF recommends screening men aged 20 to 35 for lipid disorders if they are at increased risk for CHD. (Grade B recommendation) Screening Women at Increased Risk1) The USPSTF strongly recommends screening women aged 45 and older for lipid disorders if they are at increased risk for coronary heart disease. (Grade A recommendation) 2) The USPSTF recommends screening women aged 20 to 45 for lipid disorders if they are at increased risk for CHD. (Grade B recommendation) Screening of Young Men and All Women Not at Increased Risk1) The USPSTF makes no recommendation for or against routine screening for lipid disorders in men aged 20 to 35, or in women aged 20 and older who are not at increased risk for CHD. (Grade C recommendation) Clinical Considerations1) An age to stop screening has not been established. Screening may be appropriate in older people who have never been screened; repeated screening is less important in older people because lipid levels are less likely to increase after age 65. However, because older adults have an increased baseline risk for coronary heart disease, they stand to gain greater absolute benefit from the treatment of dyslipidemia, compared with younger adults.
|
” |